Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-04-11

AUTHORS

Eijiro Nagasaki, Rei Kudo, Miho Tamura, Kazumi Hayashi, Tadashi Uwagawa, Yoshikazu Kijima, Hiroko Nogi, Hiroshi Takeyama, Masafumi Suzuki, Masako Nishikawa, Shingo Yano, Tadashi Kobayashi

ABSTRACT

BackgroundOligometastatic breast cancer (OMBC) is characterized by limited metastatic tumor numbers and sites. We have reported a 20-year overall survival (OS) rate and relapse-free rate (RFR) of 34.1% and 27.4%, respectively, in a retrospective analysis of OMBC patients treated with curative intent including a multidisciplinary approach. Metastatic breast cancer (MBC) is generally incurable; however, OMBC might be a potentially curable subset. The previous analysis included isolated locoregional recurrence (ILRR) cases, which differs from distant metastasis in treatment strategies. Therefore, in this study, we excluded ILRR cases and provided an update on clinical outcomes. We also performed a detailed subgroup analysis of OMBC patients by introducing new prognostic variables.MethodsData of 73 OMBC patients, including 10 ILRR cases, treated in our institution between 1980 and 2010 were retrospectively analyzed. OMBC was defined as the presence of metastatic lesions in 1–2 organs, < 5 lesions per metastasized organ, and lesion diameter < 5 cm.ResultsThe median follow-up duration was 151 (range 12–350) months. Twenty-eight (44%) patients received local therapy. Excluding ILRR cases, the OS rates were 28.3% and 18.9% and RFRs were 26.7% at 20 and 25 years, respectively. In multivariate analysis, single-organ involvement and three or fewer metastatic lesions per organ were associated with a longer progression-free and relapse-free interval (RFI).ConclusionsRelapse-free interval reached a plateau after 20 years at approximately 25% probability. Patients with long-term survival without disease relapse are considered cured. Curative-intent therapy should be considered for OMBC patients, especially those with low tumor volume. More... »

PAGES

1051-1061

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12282-021-01240-1

DOI

http://dx.doi.org/10.1007/s12282-021-01240-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1137128323

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33840010


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Progression-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagasaki", 
        "givenName": "Eijiro", 
        "id": "sg:person.01130456667.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130456667.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kudo", 
        "givenName": "Rei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tamura", 
        "givenName": "Miho", 
        "id": "sg:person.0714572541.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714572541.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hayashi", 
        "givenName": "Kazumi", 
        "id": "sg:person.0675623402.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675623402.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uwagawa", 
        "givenName": "Tadashi", 
        "id": "sg:person.0617176340.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617176340.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Department of Radiology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kijima", 
        "givenName": "Yoshikazu", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nogi", 
        "givenName": "Hiroko", 
        "id": "sg:person.01174224542.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174224542.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takeyama", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01107475273.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107475273.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Department of Pathology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Masafumi", 
        "id": "sg:person.011664527024.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011664527024.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Support Center, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Clinical Research Support Center, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishikawa", 
        "givenName": "Masako", 
        "id": "sg:person.014155753236.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014155753236.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yano", 
        "givenName": "Shingo", 
        "id": "sg:person.01265010246.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265010246.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobayashi", 
        "givenName": "Tadashi", 
        "id": "sg:person.014712153764.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014712153764.36"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10549-017-4228-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084762081", 
          "https://doi.org/10.1007/s10549-017-4228-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11845-018-1746-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100750082", 
          "https://doi.org/10.1007/s11845-018-1746-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2012.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028358194", 
          "https://doi.org/10.1038/bmt.2012.244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-008-0157-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043237818", 
          "https://doi.org/10.1007/s10549-008-0157-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2011.44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025733320", 
          "https://doi.org/10.1038/nrclinonc.2011.44"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12282-012-0347-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036661226", 
          "https://doi.org/10.1007/s12282-012-0347-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-04-11", 
    "datePublishedReg": "2021-04-11", 
    "description": "BackgroundOligometastatic breast cancer (OMBC) is characterized by limited metastatic tumor numbers and sites. We have reported a 20-year overall survival (OS) rate and relapse-free rate (RFR) of 34.1% and 27.4%, respectively, in a retrospective analysis of OMBC patients treated with curative intent including a multidisciplinary approach. Metastatic breast cancer (MBC) is generally incurable; however, OMBC might be a potentially curable subset. The previous analysis included isolated locoregional recurrence (ILRR) cases, which differs from distant metastasis in treatment strategies. Therefore, in this study, we excluded ILRR cases and provided an update on clinical outcomes. We also performed a detailed subgroup analysis of OMBC patients by introducing new prognostic variables.MethodsData of 73 OMBC patients, including 10 ILRR cases, treated in our institution between 1980 and 2010 were retrospectively analyzed. OMBC was defined as the presence of metastatic lesions in 1\u20132 organs,\u2009<\u20095 lesions per metastasized organ, and lesion diameter\u2009<\u20095\u00a0cm.ResultsThe median follow-up duration was 151 (range 12\u2013350) months. Twenty-eight (44%) patients received local therapy. Excluding ILRR cases, the OS rates were 28.3% and 18.9% and RFRs were 26.7% at 20 and 25\u00a0years, respectively. In multivariate analysis, single-organ involvement and three or fewer metastatic lesions per organ were associated with a longer progression-free and relapse-free interval (RFI).ConclusionsRelapse-free interval reached a plateau after 20\u00a0years at approximately 25% probability. Patients with long-term survival without disease relapse are considered cured. Curative-intent therapy should be considered for OMBC patients, especially those with low tumor volume.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12282-021-01240-1", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "keywords": [
      "relapse-free rate", 
      "metastatic breast cancer", 
      "relapse-free interval", 
      "curative intent", 
      "metastatic lesions", 
      "breast cancer", 
      "oligometastatic breast cancer patients", 
      "curative-intent therapy", 
      "overall survival rate", 
      "single organ involvement", 
      "long-term outcomes", 
      "breast cancer patients", 
      "lower tumor volume", 
      "long-term survival", 
      "detailed subgroup analysis", 
      "new prognostic variable", 
      "curable subset", 
      "median follow", 
      "OS rates", 
      "local therapy", 
      "tumor number", 
      "distant metastasis", 
      "clinical outcomes", 
      "disease relapse", 
      "recurrence cases", 
      "subgroup analysis", 
      "cancer patients", 
      "treatment strategies", 
      "retrospective analysis", 
      "tumor volume", 
      "prognostic variables", 
      "patients", 
      "survival rate", 
      "multivariate analysis", 
      "lesion diameter", 
      "lesions", 
      "multidisciplinary approach", 
      "therapy", 
      "cancer", 
      "organs", 
      "OMBC", 
      "outcomes", 
      "relapse", 
      "metastasis", 
      "MethodsData", 
      "follow", 
      "years", 
      "cases", 
      "months", 
      "interval", 
      "survival", 
      "rate", 
      "duration", 
      "involvement", 
      "report", 
      "intent", 
      "subset", 
      "analysis", 
      "study", 
      "update", 
      "volume", 
      "presence", 
      "institutions", 
      "strategies", 
      "sites", 
      "variables", 
      "number", 
      "diameter", 
      "previous analyses", 
      "probability", 
      "plateau", 
      "approach"
    ], 
    "name": "Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report", 
    "pagination": "1051-1061", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1137128323"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12282-021-01240-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33840010"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12282-021-01240-1", 
      "https://app.dimensions.ai/details/publication/pub.1137128323"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_896.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12282-021-01240-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01240-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01240-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01240-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01240-1'


 

This table displays all metadata directly associated to this object as RDF triples.

292 TRIPLES      21 PREDICATES      116 URIs      102 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12282-021-01240-1 schema:about N116c1c5785b244c9832885ceccf88fb6
2 N12fb53e2c90a4c33b865b001e141a617
3 N5ee813efdaa44447a4bd16edc6012386
4 N690c83034933434cb587ee233370333d
5 N76bb99fddd164fd1bc26275d94e991f0
6 N8012f11c2afe4dba91b7f80258c2e842
7 N8d2b44face934c108e0490c8d5fc1952
8 N9a112e28b09346a4b3712ce9b137cfb2
9 Na0f20495f75a4cc3b7122ed2d298babb
10 Na1f0d3848c704e8eb1ec524f0d294c76
11 Naf89b5136e904be5a8fc3cfa176c8992
12 Nd25a01c1003042829f261eb58783be36
13 Ne98f276fc5c14bf6a862f28b15e3a193
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author Nc9f1df1ad96f4be2aac0b45cd2b5e240
17 schema:citation sg:pub.10.1007/s10549-008-0157-4
18 sg:pub.10.1007/s10549-017-4228-2
19 sg:pub.10.1007/s11845-018-1746-9
20 sg:pub.10.1007/s12282-012-0347-0
21 sg:pub.10.1038/bmt.2012.244
22 sg:pub.10.1038/nrclinonc.2011.44
23 schema:datePublished 2021-04-11
24 schema:datePublishedReg 2021-04-11
25 schema:description BackgroundOligometastatic breast cancer (OMBC) is characterized by limited metastatic tumor numbers and sites. We have reported a 20-year overall survival (OS) rate and relapse-free rate (RFR) of 34.1% and 27.4%, respectively, in a retrospective analysis of OMBC patients treated with curative intent including a multidisciplinary approach. Metastatic breast cancer (MBC) is generally incurable; however, OMBC might be a potentially curable subset. The previous analysis included isolated locoregional recurrence (ILRR) cases, which differs from distant metastasis in treatment strategies. Therefore, in this study, we excluded ILRR cases and provided an update on clinical outcomes. We also performed a detailed subgroup analysis of OMBC patients by introducing new prognostic variables.MethodsData of 73 OMBC patients, including 10 ILRR cases, treated in our institution between 1980 and 2010 were retrospectively analyzed. OMBC was defined as the presence of metastatic lesions in 1–2 organs, < 5 lesions per metastasized organ, and lesion diameter < 5 cm.ResultsThe median follow-up duration was 151 (range 12–350) months. Twenty-eight (44%) patients received local therapy. Excluding ILRR cases, the OS rates were 28.3% and 18.9% and RFRs were 26.7% at 20 and 25 years, respectively. In multivariate analysis, single-organ involvement and three or fewer metastatic lesions per organ were associated with a longer progression-free and relapse-free interval (RFI).ConclusionsRelapse-free interval reached a plateau after 20 years at approximately 25% probability. Patients with long-term survival without disease relapse are considered cured. Curative-intent therapy should be considered for OMBC patients, especially those with low tumor volume.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf Nc8688dcf6ffe41a589168e596e3b312f
29 Ndd588b191e4b43f19b88ccaec018f838
30 sg:journal.1021080
31 schema:keywords MethodsData
32 OMBC
33 OS rates
34 analysis
35 approach
36 breast cancer
37 breast cancer patients
38 cancer
39 cancer patients
40 cases
41 clinical outcomes
42 curable subset
43 curative intent
44 curative-intent therapy
45 detailed subgroup analysis
46 diameter
47 disease relapse
48 distant metastasis
49 duration
50 follow
51 institutions
52 intent
53 interval
54 involvement
55 lesion diameter
56 lesions
57 local therapy
58 long-term outcomes
59 long-term survival
60 lower tumor volume
61 median follow
62 metastasis
63 metastatic breast cancer
64 metastatic lesions
65 months
66 multidisciplinary approach
67 multivariate analysis
68 new prognostic variable
69 number
70 oligometastatic breast cancer patients
71 organs
72 outcomes
73 overall survival rate
74 patients
75 plateau
76 presence
77 previous analyses
78 probability
79 prognostic variables
80 rate
81 recurrence cases
82 relapse
83 relapse-free interval
84 relapse-free rate
85 report
86 retrospective analysis
87 single organ involvement
88 sites
89 strategies
90 study
91 subgroup analysis
92 subset
93 survival
94 survival rate
95 therapy
96 treatment strategies
97 tumor number
98 tumor volume
99 update
100 variables
101 volume
102 years
103 schema:name Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report
104 schema:pagination 1051-1061
105 schema:productId N4f447606f928474da3728d06300b04dc
106 N6aff267269784f5287fe0df5802a63d5
107 Na898296736dc48c79709beb976bd7ade
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137128323
109 https://doi.org/10.1007/s12282-021-01240-1
110 schema:sdDatePublished 2022-08-04T17:12
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher Ne5e911677f43487a9af868987e94ae37
113 schema:url https://doi.org/10.1007/s12282-021-01240-1
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N116c1c5785b244c9832885ceccf88fb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Adult
119 rdf:type schema:DefinedTerm
120 N11fe939635e64ee696fa69d52eb053ae rdf:first sg:person.014712153764.36
121 rdf:rest rdf:nil
122 N12fb53e2c90a4c33b865b001e141a617 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Breast Neoplasms
124 rdf:type schema:DefinedTerm
125 N3277f8cf19824af8ad7d26bedfccab7f rdf:first sg:person.0675623402.52
126 rdf:rest N438057add83442adb995d5b95f96399e
127 N34d88026d1794afb9203eddda448035d rdf:first sg:person.0714572541.29
128 rdf:rest N3277f8cf19824af8ad7d26bedfccab7f
129 N438057add83442adb995d5b95f96399e rdf:first sg:person.0617176340.44
130 rdf:rest N5afa114b9eec4224a2e71695b73b1ae4
131 N4f447606f928474da3728d06300b04dc schema:name pubmed_id
132 schema:value 33840010
133 rdf:type schema:PropertyValue
134 N4f68447b05f744128d8db9a6ae7ec7d7 rdf:first sg:person.011664527024.29
135 rdf:rest N62ce01a8dcfc41b6ad8bc6aa3b2db0d1
136 N5afa114b9eec4224a2e71695b73b1ae4 rdf:first Ne8397b89108c4ff5bcf848226635f1ed
137 rdf:rest Ncd46db0b4c36497bbc7ea304923e436c
138 N5ee813efdaa44447a4bd16edc6012386 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Retrospective Studies
140 rdf:type schema:DefinedTerm
141 N62ce01a8dcfc41b6ad8bc6aa3b2db0d1 rdf:first sg:person.014155753236.54
142 rdf:rest Nc1a854c035894f81820162d8bdab7dc5
143 N690c83034933434cb587ee233370333d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Neoadjuvant Therapy
145 rdf:type schema:DefinedTerm
146 N6aff267269784f5287fe0df5802a63d5 schema:name dimensions_id
147 schema:value pub.1137128323
148 rdf:type schema:PropertyValue
149 N76bb99fddd164fd1bc26275d94e991f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Aged
151 rdf:type schema:DefinedTerm
152 N7d459419af1342b1806c5ecf88c26568 schema:affiliation grid-institutes:grid.411898.d
153 schema:familyName Kudo
154 schema:givenName Rei
155 rdf:type schema:Person
156 N8012f11c2afe4dba91b7f80258c2e842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Neoplasm Recurrence, Local
158 rdf:type schema:DefinedTerm
159 N8d2b44face934c108e0490c8d5fc1952 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Progression-Free Survival
161 rdf:type schema:DefinedTerm
162 N9a112e28b09346a4b3712ce9b137cfb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Female
164 rdf:type schema:DefinedTerm
165 Na0f20495f75a4cc3b7122ed2d298babb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Combined Modality Therapy
167 rdf:type schema:DefinedTerm
168 Na1f0d3848c704e8eb1ec524f0d294c76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Disease-Free Survival
170 rdf:type schema:DefinedTerm
171 Na898296736dc48c79709beb976bd7ade schema:name doi
172 schema:value 10.1007/s12282-021-01240-1
173 rdf:type schema:PropertyValue
174 Naf89b5136e904be5a8fc3cfa176c8992 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Neoplasm Metastasis
176 rdf:type schema:DefinedTerm
177 Nb8de0332561e4f6498e039b112fe32c3 rdf:first N7d459419af1342b1806c5ecf88c26568
178 rdf:rest N34d88026d1794afb9203eddda448035d
179 Nc1a854c035894f81820162d8bdab7dc5 rdf:first sg:person.01265010246.42
180 rdf:rest N11fe939635e64ee696fa69d52eb053ae
181 Nc3d61677b3db4957b4b5e004295aff9e rdf:first sg:person.01107475273.50
182 rdf:rest N4f68447b05f744128d8db9a6ae7ec7d7
183 Nc8688dcf6ffe41a589168e596e3b312f schema:volumeNumber 28
184 rdf:type schema:PublicationVolume
185 Nc9f1df1ad96f4be2aac0b45cd2b5e240 rdf:first sg:person.01130456667.57
186 rdf:rest Nb8de0332561e4f6498e039b112fe32c3
187 Ncd46db0b4c36497bbc7ea304923e436c rdf:first sg:person.01174224542.15
188 rdf:rest Nc3d61677b3db4957b4b5e004295aff9e
189 Nd25a01c1003042829f261eb58783be36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Middle Aged
191 rdf:type schema:DefinedTerm
192 Ndd588b191e4b43f19b88ccaec018f838 schema:issueNumber 5
193 rdf:type schema:PublicationIssue
194 Ne5e911677f43487a9af868987e94ae37 schema:name Springer Nature - SN SciGraph project
195 rdf:type schema:Organization
196 Ne8397b89108c4ff5bcf848226635f1ed schema:affiliation grid-institutes:grid.411898.d
197 schema:familyName Kijima
198 schema:givenName Yoshikazu
199 rdf:type schema:Person
200 Ne98f276fc5c14bf6a862f28b15e3a193 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Humans
202 rdf:type schema:DefinedTerm
203 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
204 schema:name Medical and Health Sciences
205 rdf:type schema:DefinedTerm
206 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
207 schema:name Oncology and Carcinogenesis
208 rdf:type schema:DefinedTerm
209 sg:journal.1021080 schema:issn 1340-6868
210 1880-4233
211 schema:name Breast Cancer
212 schema:publisher Springer Nature
213 rdf:type schema:Periodical
214 sg:person.01107475273.50 schema:affiliation grid-institutes:grid.411898.d
215 schema:familyName Takeyama
216 schema:givenName Hiroshi
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107475273.50
218 rdf:type schema:Person
219 sg:person.01130456667.57 schema:affiliation grid-institutes:grid.411898.d
220 schema:familyName Nagasaki
221 schema:givenName Eijiro
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130456667.57
223 rdf:type schema:Person
224 sg:person.011664527024.29 schema:affiliation grid-institutes:grid.411898.d
225 schema:familyName Suzuki
226 schema:givenName Masafumi
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011664527024.29
228 rdf:type schema:Person
229 sg:person.01174224542.15 schema:affiliation grid-institutes:grid.411898.d
230 schema:familyName Nogi
231 schema:givenName Hiroko
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174224542.15
233 rdf:type schema:Person
234 sg:person.01265010246.42 schema:affiliation grid-institutes:grid.411898.d
235 schema:familyName Yano
236 schema:givenName Shingo
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265010246.42
238 rdf:type schema:Person
239 sg:person.014155753236.54 schema:affiliation grid-institutes:grid.411898.d
240 schema:familyName Nishikawa
241 schema:givenName Masako
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014155753236.54
243 rdf:type schema:Person
244 sg:person.014712153764.36 schema:affiliation grid-institutes:grid.411898.d
245 schema:familyName Kobayashi
246 schema:givenName Tadashi
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014712153764.36
248 rdf:type schema:Person
249 sg:person.0617176340.44 schema:affiliation grid-institutes:grid.411898.d
250 schema:familyName Uwagawa
251 schema:givenName Tadashi
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617176340.44
253 rdf:type schema:Person
254 sg:person.0675623402.52 schema:affiliation grid-institutes:grid.411898.d
255 schema:familyName Hayashi
256 schema:givenName Kazumi
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675623402.52
258 rdf:type schema:Person
259 sg:person.0714572541.29 schema:affiliation grid-institutes:grid.411898.d
260 schema:familyName Tamura
261 schema:givenName Miho
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714572541.29
263 rdf:type schema:Person
264 sg:pub.10.1007/s10549-008-0157-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043237818
265 https://doi.org/10.1007/s10549-008-0157-4
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s10549-017-4228-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084762081
268 https://doi.org/10.1007/s10549-017-4228-2
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/s11845-018-1746-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100750082
271 https://doi.org/10.1007/s11845-018-1746-9
272 rdf:type schema:CreativeWork
273 sg:pub.10.1007/s12282-012-0347-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036661226
274 https://doi.org/10.1007/s12282-012-0347-0
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
277 https://doi.org/10.1038/bmt.2012.244
278 rdf:type schema:CreativeWork
279 sg:pub.10.1038/nrclinonc.2011.44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025733320
280 https://doi.org/10.1038/nrclinonc.2011.44
281 rdf:type schema:CreativeWork
282 grid-institutes:grid.411898.d schema:alternateName Clinical Research Support Center, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan
283 Department of Pathology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan
284 Department of Radiology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan
285 Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan
286 Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan
287 schema:name Clinical Research Support Center, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan
288 Department of Pathology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan
289 Department of Radiology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, 105-8461, Tokyo, Japan
290 Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan
291 Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan
292 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...